Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non-Small-Cell Lung Carcinoma and is Antibody Dependent

被引:157
作者
Conklin, Chris M. J. [1 ]
Craddock, Kenneth J. [2 ]
Have, Cherry [2 ]
Laskin, Janessa [1 ,3 ]
Couture, Christian [4 ,5 ]
Ionescu, Diana N. [1 ,6 ]
机构
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[2] Toronto Gen Hosp, Dept Pathol, Univ Hlth Network, Toronto, ON, Canada
[3] BC Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
[4] Hop Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada
[5] Univ Laval, Quebec City, PQ, Canada
[6] BC Canc Agcy, Dept Pathol, Vancouver, BC V5Z 4E6, Canada
关键词
Immunohistochemistry; Fluorescence in situ hybridization; Anaplastic lymphoma receptor tyrosine kinase rearrangement; Non-small-cell lung carcinoma; EML4-ALK FUSION GENE; CLINICAL-RESPONSE; CANCER PATIENTS; MUTATIONS; INHIBITOR; GEFITINIB; ADENOCARCINOMAS; TRANSLOCATION;
D O I
10.1097/JTO.0b013e318274a83e
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Fluorescence in situ hybridization (FISH) is the standard procedure for the detection of anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement in non-small-cell lung carcinoma (NSCLC) but is expensive and time consuming. We tested three antibodies to ALK, using various detection systems, and hypothesized that ALK immunohistochemistry (IHC) may represent a cost-effective and efficient means of screening for ALK rearrangement in NSCLC. Methods: We screened 377 stage I or II NSCLC cases in a tissue microarray by FISH and IHC (5A4 [Leica Biosystems Newcastle Ltd, Newcastle upon Tyne, UYnited Kingdom] by Nichirei's N-Histofine ALK detection kit [Nichirei Biosciences inc., Tokyo, Japan], 5A4 by Novocastra with ADVANCE [Dako Canada inc., Burlington, Ontario, Canada], D5F3 by Cell Signaling Technology with ADVANCE [Cell Signalling Technologies inc., Danvers, MA], and DAKO clone ALK1 with FLEX [Dako Canada inc., Burlington, Ontario, Canada] and ADVANCE). IHC was scored as 0, 1+, 2+, or 3+. Possibly positive or positive cases were further analyzed by IHC and FISH on whole section. Results: Tissue microarray results were available on 377 cases by IHC and 273 cases by FISH. Eleven cases were positive or possibly positive by either IHC or FISH, and three cases were positive or possibly positive by both methods. Three cases were ALK-positive by FISH on whole section validation. There was no correlation between semiquantitative IHC score (1+, 2+, 3+) and ALK rearrangement by FISH. D5F3 (Cell Signaling by ADVANCE) and 5A4 (Novocastra by ADVANCE) showed the greatest combination of sensitivity (100%) and specificity (87.5% for 5A4 by Novocastra and 75% for D5F3 by Cell Signaling), and produced no false--negative results. Conclusions: IHC is a reliable screening tool for identification of ALK rearrangement in NSCLC and is antibody dependent. D5F3 Cell Signaling) and 5A4 (Novocastra) can be used with FISH for identification of IHC-positive cases to reduce screening costs.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 29 条
[1]  
[Anonymous], J CLIN ONCOL
[2]   The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers [J].
Atherly, A. J. ;
Camidge, D. R. .
BRITISH JOURNAL OF CANCER, 2012, 106 (06) :1100-1106
[3]   Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas [J].
Boland, Jennifer M. ;
Erdogan, Sibel ;
Vasmatzis, George ;
Yang, Ping ;
Tillmans, Lori S. ;
Johnson, Michele R. Erickson ;
Wang, Xiaoke ;
Peterson, Lisa M. ;
Halling, Kevin C. ;
Oliveira, Andre M. ;
Aubry, Marie Christine ;
Yi, Eunhee S. .
HUMAN PATHOLOGY, 2009, 40 (08) :1152-1158
[4]   Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). [J].
Camidge, D. R. ;
Bang, Y. ;
Kwak, E. L. ;
Shaw, A. T. ;
Iafrate, A. J. ;
Maki, R. G. ;
Solomon, B. J. ;
Ou, S. I. ;
Salgia, R. ;
Wilner, K. D. ;
Costa, D. B. ;
Shapiro, G. ;
LoRusso, P. ;
Stephenson, P. ;
Tang, Y. ;
Ruffner, K. ;
Clark, J. W. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5]   Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment [J].
Camidge, D. Ross ;
Kono, Scott A. ;
Flacco, Antonella ;
Tan, Aik-Choon ;
Doebele, Robert C. ;
Zhou, Qing ;
Crino, Lucio ;
Franklin, Wilbur A. ;
Varella-Garcia, Marileila .
CLINICAL CANCER RESEARCH, 2010, 16 (22) :5581-5590
[6]   EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors [J].
Choi, Young Lim ;
Soda, Manabu ;
Yamashita, Yoshihiro ;
Ueno, Toshihide ;
Takashima, Junpei ;
Nakajima, Takahiro ;
Yatabe, Yasushi ;
Takeuchi, Kengo ;
Hamada, Toru ;
Haruta, Hidenori ;
Ishikawa, Yuichi ;
Kimura, Hideki ;
Mitsudomi, Tetsuya ;
Tanio, Yoshiro ;
Mano, Hiroyuki .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1734-1739
[7]   EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset [J].
Inamura, Kentaro ;
Takeuchi, Kengo ;
Togashi, Yuki ;
Hatano, Satoko ;
Ninomiya, Hironori ;
Motoi, Noriko ;
Mun, Ming-yon ;
Sakao, Yukinori ;
Okumura, Sakae ;
Nakagawa, Ken ;
Soda, Manabu ;
Choi, Young Lim ;
Mano, Hiroyuki ;
Ishikawa, Yuichi .
MODERN PATHOLOGY, 2009, 22 (04) :508-515
[8]   Nonsmall cell lung carcinoma with neuroendocrine differentiation - An entity of no clinical or prognostic significance [J].
Ionescu, Diana N. ;
Treaba, Diana ;
Gilks, Cyril B. ;
Leung, Samuel ;
Renouf, Daniel ;
Laskin, Janessa ;
Wood-Baker, Richard ;
Gown, Allen M. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (01) :26-32
[9]   Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival [J].
Jemal, A ;
Clegg, LX ;
Ward, E ;
Ries, LAG ;
Wu, XC ;
Jamison, PM ;
Wingo, PA ;
Howe, HL ;
Anderson, RN ;
Edwards, BK .
CANCER, 2004, 101 (01) :3-27
[10]   Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world [J].
Kamangar, Farin ;
Dores, Graca M. ;
Anderson, William F. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) :2137-2150